Definitive Healthcare (NASDAQ:DH - Get Free Report) issued an update on its third quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.050-0.060 for the period, compared to the consensus EPS estimate of 0.058. The company issued revenue guidance of $59.0 million-$60.0 million, compared to the consensus revenue estimate of $59.2 million. Definitive Healthcare also updated its FY 2025 guidance to 0.220-0.230 EPS.
Definitive Healthcare Price Performance
Shares of Definitive Healthcare stock traded up $0.04 during trading hours on Thursday, reaching $3.97. The company's stock had a trading volume of 680,471 shares, compared to its average volume of 409,646. The firm has a 50 day moving average price of $3.88 and a 200-day moving average price of $3.63. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. The stock has a market cap of $590.10 million, a P/E ratio of 32.75, a P/E/G ratio of 6.62 and a beta of 1.64. Definitive Healthcare has a one year low of $2.15 and a one year high of $5.68.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.03). Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. On average, analysts predict that Definitive Healthcare will post 0.16 EPS for the current year.
Wall Street Analyst Weigh In
DH has been the topic of several research reports. The Goldman Sachs Group raised their price target on Definitive Healthcare from $3.00 to $3.40 and gave the company a "neutral" rating in a research note on Monday, May 12th. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Finally, BTIG Research downgraded shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Definitive Healthcare currently has a consensus rating of "Hold" and a consensus price target of $4.73.
Get Our Latest Report on Definitive Healthcare
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. Jane Street Group LLC increased its stake in shares of Definitive Healthcare by 166.0% in the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company's stock valued at $304,000 after purchasing an additional 65,597 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after purchasing an additional 7,404,363 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Definitive Healthcare by 56.7% in the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company's stock valued at $1,706,000 after purchasing an additional 213,562 shares during the period. Institutional investors and hedge funds own 98.67% of the company's stock.
Definitive Healthcare Company Profile
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
